PDF
(Download)
|
- Turmeric (Curcuma longa, Zingiberaceae)
- Curcuminoids
- Osteoarthritis
|
Date:
01-15-2015 | HC# 081424-512
|
Re: Curcuminoid Supplementation Improves Knee Osteoarthritis Symptoms
Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi
A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind
placebo-controlled trial. Phytother Res. November
2014;28(11):1625-1631.
The
most common joint disease in adults, osteoarthritis (OA) is characterized by
chronic joint pain, inflammation, stiffness, and limited mobility. Standard
treatment is the prescription of analgesics and non-steroidal anti-inflammatory
drugs (NSAIDs); however, NSAIDs are only partially effective and may cause
adverse gastrointestinal, renal, and cardiovascular effects. Experimental
studies have found that the curcuminoid constituents (2-5%) of turmeric (Curcuma longa, Zingiberaceae) have
significant analgesic, anti-inflammatory, and antioxidant properties. Preliminary
clinical evidence suggests curcuminoids may be an effective alternative or adjunct
treatment for OA. In this randomized, double-blind, placebo-controlled pilot
study, the effect of curcuminoid supplementation on clinical measures of knee OA
symptoms was measured.
Patients
under the age of 80 with mild-to-moderate knee OA (n=60) were recruited from
Baqiyatallah University Clinic in Tehran, Iran. Diagnoses of knee OA were based
on the clinical and radiological criteria of the American College of
Rheumatology and a minimum score of 40 mm on a 100 mm visual analog scale (VAS)
of joint pain. The exclusion criteria were as follows: known allergy to
curcuminoids or other herbs; candidates for knee replacement or any other surgery;
OA secondary to trauma; rheumatoid arthritis, inflammatory disorders, or
hemophilia; malabsorption disorders; active, generalized inflammatory
conditions; heart, renal, or liver failure; history of psychological disorders;
using ˃10 mg/day corticosteroids in the prior 3 months; and intra-articular injections
in the last 3 months.
The
eligible consenting patients (n=53) were consecutively randomly assigned to
receive either 500 mg 3x/day (1500 mg/day) of curcuminoids (n=27; C3 Complex®;
Sami Labs Ltd; Bangalore, India) or a size- and shape-matched placebo (n=26; inert
starch) for 6 weeks. Each C3 Complex capsule contained 500 mg curcuminoids and
5 mg BioPerine® (Sami Labs Ltd). BioPerine is a standardized
extract of black pepper (Piper nigrum,
Piperaceae) and/or long pepper (Piper
longum) containing at least 95% piperine, which has been shown to increase
the absorption of curcuminoids. All patients were allowed to use an escape
medication (naproxen) when they had intolerable pain.
The
change in OA symptoms was measured with the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC), OA pain severity rating on VAS, and the
5-item Lequesne's Pain Functional Index (LPFI). Adverse effects were recorded
using a pre-designed checklist.
Forty
patients completed the study with 19 in the treatment group and 21 in the
placebo group. Eight patients in the treatment group and 5 patients in the
placebo group were lost to follow-up. No reasons for the losses in either group
were given. All patients were taking NSAIDs at baseline.
At
the end of the study, there were significant reductions in the global WOMAC
score and the pain, physical function, and stiffness subcategory scores in the
treatment group (P < 0.001, P < 0.001, P < 0.001, and P = 0.043,
respectively) compared to baseline. The scores for the WOMAC pain and stiffness
subcategories were also significantly reduced in the placebo group (P = 0.025
and P = 0.009, respectively) compared to baseline. However, the global WOMAC
score and scores for the subcategories of pain and physical function were all
significantly lower in the treatment group compared to the placebo group at the
end of the study (P = 0.001, P < 0.002, and P < 0.001, respectively). There
was no significant difference between the treatment and placebo groups in the
WOMAC stiffness subcategory.
Treatment
with curcuminoids (but not placebo) significantly improved both the VAS and
LPFI scores (P < 0.001 for both) compared to baseline. Compared to the
placebo group, the magnitude of reduction in VAS and LPFI scores was
significantly greater in the treatment group (P = 0.013 and P < 0.001,
respectively). There was also a significant reduction (P < 0.001) in the use
of NSAIDs in the treatment group (84%) compared to the placebo group (19%). No
serious adverse events (AEs) were reported, and none of the dropouts were due
to AEs. The most common AE was gastrointestinal distress with 7 patients in the
treatment group and 4 in the placebo group affected.
Six
weeks of curcuminoid supplementation resulted in marked improvement in symptoms
of knee OA compared to the placebo. In addition, there was a significant
reduction in the use of NSAIDs in the group taking curcuminoid supplements. The
authors suggest that a plausible mechanism is the potent anti-inflammatory and
antioxidant properties of curcuminoids. Curcuminoids have been shown to reduce
the release of pro-inflammatory cytokines in cultured chondrocytes, increase
chondrocyte survival, inhibit the production of reactive oxygen species which
impair joint components, and scavenge free radicals which disrupt the cartilage
matrix and promote the production of pain mediators.
The
authors note several limitations of the study, including the small sample size
and short duration, as well as the facts that the optimum dose and
dose-response relationship were not determined and only patients with mild-to-moderate
OA were evaluated. Based upon the positive safety and efficacy findings in this
study, the authors conclude that larger scale (Phase III) trials should be
conducted to confirm the results and investigate whether the effect is
independent of analgesic mechanisms.
–Cheryl
McCutchan, PhD
|